Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus rating of “Buy” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.00.

PYXS has been the topic of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Finally, Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 target price for the company.

Pyxis Oncology Stock Down 2.7 %

NASDAQ:PYXS opened at $3.62 on Friday. The business’s 50 day moving average is $3.61 and its two-hundred day moving average is $3.91. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The company has a market cap of $215.10 million, a PE ratio of -2.66 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, sell-side analysts expect that Pyxis Oncology will post -1.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology in the second quarter worth $40,000. SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology during the first quarter valued at $59,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $65,000. Schulhoff & Co. Inc. boosted its position in shares of Pyxis Oncology by 90.9% in the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Pyxis Oncology by 56.0% during the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after buying an additional 20,901 shares during the last quarter. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.